Clinical features of patients with refractory primary biliary cholangitis

[1]  W. Ben Mansour,et al.  Primary biliary cholangitis : therapeutic and evolving aspects about 46 cases. , 2018, La Tunisie medicale.

[2]  Youfu Zhu,et al.  Evidence for the association between IgG‐antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis , 2017, Journal of gastroenterology and hepatology.

[3]  T. Saibara,et al.  Autoantibody status and histological variables influence biochemical response to treatment and long‐term outcomes in Japanese patients with primary biliary cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  Martin Braddock,et al.  Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis , 2015, Medicine.

[5]  K. Lindor,et al.  Primary biliary cirrhosis , 2003, The Lancet.

[6]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[7]  B. Liu,et al.  Early biochemical response to ursodeoxycholic acid and long‐term prognosis of primary biliary cirrhosis: Results of a 14‐year cohort study , 2013, Hepatology.

[8]  D. Vergani,et al.  Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[9]  Y. Hiasa,et al.  Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis , 2009, Journal of Gastroenterology.

[10]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[11]  Masahiro Ito,et al.  Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis , 2007, Hepatology.

[12]  B. Hansen,et al.  Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.

[13]  K. Migita,et al.  Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. , 2005, Journal of hepatology.